{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T16:05:51Z","timestamp":1763481951085,"version":"3.45.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13300-025-01809-5","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T09:37:06Z","timestamp":1761298626000},"page":"2351-2363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Multicenter, Prospective, Observational, and Single-Arm Interventional Study of Mirogabalin in Diabetic Peripheral Neuropathic Pain: Rationale and Design of Dia-NeP"],"prefix":"10.1007","volume":"16","author":[{"given":"Hideki","family":"Kamiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Deguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhito","family":"Himeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiki","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"1809_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41572-019-0092-1","volume":"5","author":"EL Feldman","year":"2019","unstructured":"Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5:42.","journal-title":"Nat Rev Dis Primers"},{"key":"1809_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1212\/WNL.0000000000001160","volume":"84","author":"NA Visser","year":"2015","unstructured":"Visser NA, Notermans NC, Linssen RS, et al. Incidence of polyneuropathy in Utrecht, the Netherlands. Neurology. 2015;84:259\u201364.","journal-title":"Neurology"},{"key":"1809_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11940-011-0113-1","volume":"13","author":"L Zilliox","year":"2011","unstructured":"Zilliox L, Russell JW. Treatment of diabetic sensory polyneuropathy. Curr Treat Options Neurol. 2011;13:143\u201359.","journal-title":"Curr Treat Options Neurol"},{"key":"1809_CR4","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.2337\/dc21-0010","volume":"44","author":"L Bjerg","year":"2021","unstructured":"Bjerg L, Nicolaisen SK, Christensen DH, et al. Diabetic polyneuropathy early in type 2 diabetes is associated with higher incidence rate of cardiovascular disease: results from two Danish cohort studies. Diabetes Care. 2021;44:1714\u201321.","journal-title":"Diabetes Care"},{"key":"1809_CR5","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1111\/j.1468-1331.2011.03659.x","volume":"19","author":"WC Hsu","year":"2012","unstructured":"Hsu WC, Chiu SY, Yen AM, et al. Somatic neuropathy is an independent predictor of all- and diabetes-related mortality in type 2 diabetic patients: a population-based 5-year follow-up study (KCIS No. 29). Eur J Neurol. 2012;19:1192\u20138.\u00a0","journal-title":"Eur J Neurol"},{"key":"1809_CR6","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2337\/dc08-0433","volume":"31","author":"ES Strotmeyer","year":"2008","unstructured":"Strotmeyer ES, Rekeneire ND, Schwartz AV, et al. The relationship of reduced peripheral nerve function and diabetes with physical performance in older White and Black adults: the Health, Aging, and Body Composition (Health ABC) Study. Diabetes Care. 2008;31:1767\u201372.","journal-title":"Diabetes Care"},{"key":"1809_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/jdi.12658","volume":"9","author":"T Nomura","year":"2018","unstructured":"Nomura T, Ishiguro T, Ohira M, et al. Diabetic polyneuropathy is a risk for decline of lower extremity strength in patients with type 2 diabetes. J Diabetes Investig. 2018;9:186\u201392.","journal-title":"J Diabetes Investig"},{"key":"1809_CR8","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/jdi.13788","volume":"13","author":"K Mikura","year":"2022","unstructured":"Mikura K, Kodama E, Iida T, et al. Association between sarcopenia and the severity of diabetic polyneuropathy assessed by nerve conduction studies in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2022;13:1357\u201365.\u00a0","journal-title":"J Diabetes Investig"},{"key":"1809_CR9","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/jdi.13105","volume":"10","author":"SS Gylfadottir","year":"2019","unstructured":"Gylfadottir SS, Weeracharoenkul D, Andersen ST, Niruthisard S, Suwanwalaikorn S, Jensen TS. Painful and non-painful diabetic polyneuropathy: clinical characteristics and diagnostic issues. J Diabetes Investig. 2019;10:1148\u201357.","journal-title":"J Diabetes Investig"},{"key":"1809_CR10","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jpainsymman.2005.04.009","volume":"30","author":"M Gore","year":"2005","unstructured":"Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005;30:374\u201385.","journal-title":"J Pain Symptom Manage"},{"key":"1809_CR11","doi-asserted-by":"publisher","first-page":"2091960","DOI":"10.1155\/2019\/2091960","volume":"2019","author":"A Girach","year":"2019","unstructured":"Girach A, Julian TH, Varrassi G, Paladini A, Vadalouka A, Zis P. Quality of life in painful peripheral neuropathies: a systematic review. Pain Res Manag. 2019;2019:2091960.","journal-title":"Pain Res Manag"},{"key":"1809_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1212\/WNL.0000000000001714","volume":"85","author":"B Callaghan","year":"2015","unstructured":"Callaghan B, Kerber K, Langa KM, et al. Longitudinal patient-oriented outcomes in neuropathy: importance of early detection and falls. Neurology. 2015;85:71\u20139.","journal-title":"Neurology"},{"key":"1809_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.diabet.2008.11.004","volume":"35","author":"K Van Acker","year":"2009","unstructured":"Van Acker K, Bouhassira D, De Bacquer D. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab. 2009;35:206\u201313.","journal-title":"Diabetes Metab"},{"key":"1809_CR14","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2522\/ptj.20120070","volume":"92","author":"SD Jernigan","year":"2012","unstructured":"Jernigan SD, Pohl PS, Mahnken JD, et al. Diagnostic accuracy of fall risk assessment tools in people with diabetic peripheral neuropathy. Phys Ther. 2012;92:1461\u201370.","journal-title":"Phys Ther"},{"key":"1809_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11892-019-1212-8","volume":"19","author":"CW Hicks","year":"2019","unstructured":"Hicks CW, Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep. 2019;19:86.\u00a0","journal-title":"Curr Diab Rep"},{"key":"1809_CR16","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.2337\/dc05-2228","volume":"29","author":"M Davies","year":"2006","unstructured":"Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518\u201322.\u00a0","journal-title":"Diabetes Care"},{"key":"1809_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.diabres.2015.04.031","volume":"109","author":"CJ Alleman","year":"2015","unstructured":"Alleman CJ, Westerhout KY, Hensen M, et al. Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: a review of the literature. Diabetes Res Clin Pract. 2015;109:215\u201325.","journal-title":"Diabetes Res Clin Pract"},{"key":"1809_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.7326\/M20-1340","volume":"174","author":"Caitlin W Hicks","year":"2021","unstructured":"Hicks CW, Wang D, Matsushita K, et al. Peripheral neuropathy and all-cause and cardiovascular mortality in U.S. adults : a prospective cohort study. Ann Intern Med 2021;174(2):167\u2013174.","journal-title":"Ann Intern Med"},{"key":"1809_CR19","first-page":"799","volume":"50","author":"J Satoh","year":"2007","unstructured":"Satoh J, Baba M, Yagihashi S, et al. Frequency of diabetic polyneuropathy (DPN) and clinical significance of Achilles tendon reflex in diagnosis of DPN. J Japan Diabetes Soc. 2007;50:799\u2013806.","journal-title":"J Japan Diabetes Soc"},{"key":"1809_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/jdi.13117","volume":"11","author":"H Yokoyama","year":"2020","unstructured":"Yokoyama H, Tsuji T, Hayashi S, Kabata D, Shintani A. Factors associated with diabetic polyneuropathy-related sensory symptoms and signs in patients with polyneuropathy: a cross-sectional Japanese study (JDDM 52) using a non-linear model. J Diabetes Investig. 2020;11:450\u20137.","journal-title":"J Diabetes Investig"},{"key":"1809_CR21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/jdi.14105","volume":"15","author":"H Kamiya","year":"2024","unstructured":"Kamiya H, Himeno T, Watarai A, et al. Prevalence and characteristics of diabetic symmetric sensorimotor polyneuropathy in Japanese patients with type 2 diabetes: The Japan Diabetes Complication and its Prevention Prospective study (JDCP study 10). J Diabetes Investig. 2024;15:247\u201353.","journal-title":"J Diabetes Investig"},{"key":"1809_CR22","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1097\/j.pain.0000000000001501","volume":"160","author":"J Kato","year":"2019","unstructured":"Kato J, Matsui N, Kakehi Y, Murayama E, Ohwada S, Sugihara M. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain. 2019;160:1175\u201385.","journal-title":"Pain"},{"key":"1809_CR23","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/jdi.13013","volume":"10","author":"M Baba","year":"2019","unstructured":"Baba M, Matsui N, Kuroha M, et al. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig. 2019;10:1299\u2013306.","journal-title":"J Diabetes Investig"},{"key":"1809_CR24","doi-asserted-by":"publisher","first-page":"e1193","DOI":"10.1212\/WNL.0000000000201709","volume":"100","author":"T Ushida","year":"2023","unstructured":"Ushida T, Katayama Y, Hiasa Y, et al. Mirogabalin for central neuropathic pain after spinal cord injury: a randomized, double-blind, placebo-controlled, phase 3 study in Asia. Neurology. 2023;100:e1193\u2013206.","journal-title":"Neurology"},{"key":"1809_CR25","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s40122-023-00513-1","volume":"12","author":"T Ushida","year":"2023","unstructured":"Ushida T, Katayama Y, Hiasa Y, et al. Long-term safety and efficacy of mirogabalin for central neuropathic pain: a multinational, phase 3, 52-week, open-label study in Asia. Pain Ther. 2023;12:963\u201378.","journal-title":"Pain Ther"},{"key":"1809_CR26","unstructured":"Mirogabalin besylate (Tarlige\u24c7) tablets [package insert, version 9]. Daiichi Sankyo Co., Ltd.; Tokyo, Japan: 2025. Available from: https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00070625.pdf [In Japanese]. Accessed 21 Feb 2025."},{"key":"1809_CR27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/jdi.13178","volume":"11","author":"M Baba","year":"2020","unstructured":"Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain. J Diabetes Investig. 2020;11:693\u20138.","journal-title":"J Diabetes Investig"},{"key":"1809_CR28","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s40122-024-00617-2","volume":"13","author":"X Guo","year":"2024","unstructured":"Guo X, Yu Y, Zhang Y, et al. A phase 3, multicenter, randomized, double-blind, placebo-controlled 14-week study of mirogabalin in Chinese patients with diabetic peripheral neuropathic pain. Pain Ther. 2024;13:937\u201352.\u00a0","journal-title":"Pain Ther"},{"key":"1809_CR29","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727\u201336.","journal-title":"Qual Life Res"},{"key":"1809_CR30","volume-title":"Japanese Clinical Practice Guideline for Diabetes 2024","author":"Japanese Diabetes Society","year":"2024","unstructured":"Japanese Diabetes Society. Japanese Clinical Practice Guideline for Diabetes 2024. Tokyo, Japan: Nankodo Co. Ltd.; 2024. (In Japanese)."},{"key":"1809_CR31","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.diabres.2007.01.053","volume":"77","author":"H Yasuda","year":"2007","unstructured":"Yasuda H, Sanada M, Kitada K, et al. Rationale and usefulness of newly devised abbreviated diagnostic criteria and staging for diabetic polyneuropathy. Diabetes Res Clin Pract. 2007;77:178\u201383.","journal-title":"Diabetes Res Clin Pract"},{"key":"1809_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/bja\/aen103","volume":"101","author":"H Breivik","year":"2008","unstructured":"Breivik H, Borchgrevink PC, Allen SM, et al. Assessment of pain. Br J Anaesth. 2008;101:17\u201324.","journal-title":"Br J Anaesth"},{"key":"1809_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149\u201358.","journal-title":"Pain"},{"key":"1809_CR34","first-page":"1","volume":"49","author":"N Murase","year":"2002","unstructured":"Murase N, Katsumura T, Ueda C, Inoue S, Shimomitsu T. Validity and reliability of Japanese version of International Physical Activity Questionnaire. J Health Welfare Stat. 2002;49:1\u20139.","journal-title":"J Health Welfare Stat"},{"key":"1809_CR35","unstructured":"Japan Diabetes Prevention Council. Report on the Actual Condition of Foot Appearance Abnormality and Diabetic Neuropathy in Diabetic Patients in Japan 2008. Available from: https:\/\/www.med.or.jp\/dl-med\/tounyoubyou\/diabetes080312.pdf [in Japanese] Accessed 25 Dec 2024."},{"key":"1809_CR36","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1007\/s12325-021-01810-x","volume":"38","author":"T Deguchi","year":"2021","unstructured":"Deguchi T, Takatsuna H, Yokoyama M, et al. A cross-sectional web survey of satisfaction with treatment for pain in participants with suspected diabetic peripheral neuropathic pain in both feet. Adv Ther. 2021;38:4304\u201320.","journal-title":"Adv Ther"},{"key":"1809_CR37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.25614","volume":"7","author":"X Guo","year":"2024","unstructured":"Guo X, Zhang T, Yuan G, et al. GABA analogue HSK16149 in Chinese patients with diabetic peripheral neuropathic pain: a phase 3 randomized clinical trial. JAMA Netw Open. 2024;7:e2425614.","journal-title":"JAMA Netw Open"},{"key":"1809_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2024.108809","volume":"38","author":"KH Joung","year":"2024","unstructured":"Joung KH, Kim TN, Ku EJ, et al. A phase 4 randomized active-controlled clinical study to compare the efficacy and safety of sustained-release pregabalin with immediate-release pregabalin in type 2 diabetic patients with peripheral neuropathic pain. J Diabetes Complications. 2024;38:108809.","journal-title":"J Diabetes Complications"},{"key":"1809_CR39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40122-020-00156-6","volume":"9","author":"M Baba","year":"2020","unstructured":"Baba M, Kuroha M, Ohwada S, Murayama E, Matsui N. Results of mirogabalin treatment for diabetic peripheral neuropathic pain in Asian subjects: a phase 2, double-blind, randomized, placebo-controlled, study. Pain Ther. 2020;9:261\u201378.","journal-title":"Pain Ther"},{"key":"1809_CR40","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40200-019-00427-w","volume":"18","author":"K Joharchi","year":"2019","unstructured":"Joharchi K, Memari M, Azargashb E, Saadat N. Efficacy and safety of duloxetine and pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial. J Diabetes Metab Disord. 2019;18:575\u201382.","journal-title":"J Diabetes Metab Disord"},{"key":"1809_CR41","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2147\/JPR.S170646","volume":"11","author":"H Enomoto","year":"2018","unstructured":"Enomoto H, Yasuda H, Nishiyori A, et al. Duloxetine in patients with diabetic peripheral neuropathic pain in Japan: a randomized, double-blind, noninferiority comparative study with pregabalin. J Pain Res. 2018;11:1857\u201368.","journal-title":"J Pain Res"},{"key":"1809_CR42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.2040-1124.2011.00122.x","volume":"2","author":"J Satoh","year":"2011","unstructured":"Satoh J, Yagihashi S, Baba M, et al. Efficacy and safety evaluation of pregabalin treatment over 52 weeks in patients with diabetic neuropathic pain extended after a double-blind placebo-controlled trial. J Diabetes Investig. 2011;2:457\u201363.","journal-title":"J Diabetes Investig"},{"key":"1809_CR43","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/1753-0407.12585","volume":"10","author":"Y Mu","year":"2018","unstructured":"Mu Y, Liu X, Li Q, et al. Efficacy and safety of pregabalin for painful diabetic peripheral neuropathy in a population of Chinese patients: a randomized placebo-controlled trial. J Diabetes. 2018;10:256\u201365.","journal-title":"J Diabetes"},{"key":"1809_CR44","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1464-5491.2010.03152.x","volume":"28","author":"J Satoh","year":"2011","unstructured":"Satoh J, Yagihashi S, Baba M, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14-week, randomized, double-blind, placebo-controlled trial. Diabet Med. 2011;28:109\u201316.","journal-title":"Diabet Med"},{"key":"1809_CR45","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.2147\/JPR.S255345","volume":"13","author":"M Baba","year":"2020","unstructured":"Baba M, Takatsuna H, Matsui N, Ohwada S. Mirogabalin in Japanese patients with renal impairment and pain associated with diabetic peripheral neuropathy or post-herpetic neuralgia: a phase III, open-label, 14-week study. J Pain Res. 2020;13:1811\u201321.","journal-title":"J Pain Res"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01809-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01809-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01809-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T16:03:10Z","timestamp":1763481790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01809-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1809"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01809-5","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"type":"print","value":"1869-6953"},{"type":"electronic","value":"1869-6961"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hideki Kamiya has received speaker honoraria from Abbott Japan LLC., Arkray, Inc., Astellas Pharma Inc., AstraZeneca K.K., Bayer Yakuhin, Ltd., Nippon Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., EA Pharma Co., Ltd., Eli Lilly Japan K.K., Eisai Co., Ltd., Fukuda Denshi Co., Ltd., GlaxoSmithKline K.K., Kissei Pharmaceutical Co., Ltd., Kowa Co., Ltd., Kyowa Kirin Co., Ltd., Novartis Pharma K.K., Novo Nordisk Pharma Ltd., Mitsubishi Tanabe Pharma Corp., MSD K.K., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., Sumitomo Pharma Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and Viatris Inc.; and grant support from Nippon Boehringer Ingelheim Co., Ltd., CBC Co., Ltd., Daiichi Sankyo Co., Ltd., EA Pharma Co., Ltd., Eli Lilly Japan K.K., Fukuda Denshi Co., Ltd., Kissei Pharmaceutical Co., Ltd. Kowa Co., Ltd., Kyowa Kirin Co., Ltd., MSD K.K., Mochida Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Parexel International Corp., Sanwa Kagaku Kenkyusho Co., Ltd., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. Ryo Suzuki has received a lecture fee from Daiichi Sankyo Co., Ltd. Jun Wada has received speaker honoraria from AstraZeneca K.K., Bayer Yakuhin, Ltd., Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., Novo Nordisk Pharma Ltd., and Mitsubishi Tanabe Pharma Corp.; and grant support from Abbott Japan LLC., Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Sumitomo Pharma Co., Ltd., and Mitsubishi Tanabe Pharma Corp. Takahisa Deguchi has received a lecture fee from Daiichi Sankyo Co., Ltd. Tatsuhito Himeno has no COI to be declared. Shuhei Yamamoto and Taiki Toyama are employees of Daiichi Sankyo Co., Ltd. Jiro Nakamura has received a lecture fee from Daiichi Sankyo Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study has been approved by the Certified Review Board of Hattori Clinic (CRB3180027; approval date, 20\/December\/2024) and registered in the Japan Registry of Clinical Trials (jRCTs031240623 registered 20\/January\/2025). The study will be conducted in accordance with the Ethical Guidelines for Life Science and Medical Research Involving Human Subjects, the Act on the Protection of Personal Information, and the Declaration of Helsinki (as revised in 2013). The study will also be conducted in accordance with the Clinical Trials Act in Japan, under which clinical research is only required to undergo a central ethical review. Written informed consent will be obtained from each patient. No permissions are required for assessment scales other than EQ-5D-5L. The permission for use of EQ-5D-5L was obtained prior to study [\n                      \n                      ].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}